---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-033594"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2023-07-20T23:59:59+00:00"
generated_at: "2026-06-13T05:44:19.798525+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.05
calibrated_materiality_score: 0.05
confidence: "high"
source: SEC EDGAR
---

# Graphite Bio shareholders elect three Class II directors, ratify Deloitte as auditor

## Summary
- Abraham Bassan, Matthew Porteus, and Jo Viney elected with >35.8M votes each; 5.6M broker non-votes.
- Deloitte & Touche ratified as FY2023 auditor: 44,039,995 for, 11,869 against, 55,188 abstentions.
- Total shares entitled to vote: 58,102,949; shares present/proxy: 44,107,052.

## SEC filing metadata
- accession: 0000950170-23-033594
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2023-07-20T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.05
- calibrated_materiality_score: 0.05
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000095017023033594/0000950170-23-033594-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000095017023033594/grph-20230719.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-033594
- JSON: https://secwatch.observer/filing/0000950170-23-033594.json
- Plain text: https://secwatch.observer/filing/0000950170-23-033594.txt

## Key facts
- Shareholder Votes
  LENZ Therapeutics, Inc. shareholders approved Election of the three director nominees to the Board as Class II directors to hold office until the 2026 Annual Meeting at the 2023-07-19 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-07-19
  source text: Proposal 1 - Election of Directors The Company’s stockholders elected the three (3) director nominees below to the Company’s Board of Directors as Class II directors to hold office until the 2026 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815776/000095017023033594/0000950170-23-033594-index.htm
- Shareholder Votes
  LENZ Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Accounting Firm Deloitte & Touche LLP at the 2023-07-19 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-07-19
  source text: Proposal 2 - Ratification of Appointment of Independent Registered Accounting Firm The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815776/000095017023033594/0000950170-23-033594-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.